Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study

Table 1 Pretreatment characteristics (N = 213). KPS, karnofsky performance status; NOS, non-small cell lung cancer not otherwise specified; BED10, biologically effective dose; CT, chemotherapy; SBRT, stereotactic body radiotherapy

Variable	n	Percentage (%)
Age (yr)
Md (range)	72(38–89)
≤ 70	98	46.0
>70	115	54.0
Gender
Male	175	17.8
Female	38	82.2
KPS
90	71	33.3
80	125	58.7
70	17	8.0
History of smoking
Yes	134	62.9
No	79	37.1
Primary pulmonary diseases
Yes	85	39.9
No	128	60.1
T stage
T1	36	16.9
T2	71	33.3
T3	49	23.0
T4	57	26.8
N stage
N0	12	5.6
N1	22	10.3
N2	102	47.9
N3	77	36.2
TNM stage
IIIa	108	50.7
IIIb	61	28.6
IIIc	44	20.7
Tumor diameter
Md (range)	3.8(1.2–11.5)
<4 cm	109	51.2
≥ 4 cm	104	48.8
Pathologic pattern
Squamous cell carcinoma	93	43.7
Adenocarcinoma	109	51.2
NOS	11	5.2
Primary tumor lobe
Left upper lobe	65	30.5
Left lower lobe	25	11.7
Right upper lobe	61	28.6
Right middle lobe	18	8.5
Right lower lobe		20.7
Primary Tumor Localization
Central	86	40.4
Peripheral	127	59.6
BED₁₀
Md (range)	85.8(55–132)
≤ 85.0 Gy	79	37.1
>85.0 Gy	134	62.9
Type of systemic therapy
Induction CT + SBRT	107	50.2
Induction CT + SBRT + consolidation CT	19	8.9
Induction CT + SBRT + consolidation CT + immunotherapy	2	0.9
SBRT + consolidation CT	15	7.0
SBRT alone	70	32.9

ISSN: 1748-717X